AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32078394 — intervention group
Group type: COMPARATOR
Intervention: CASH‐AA Only
Number of subjects: 145
Study 32621730 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized obesity
Number of subjects: 10037
Study 32621730 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal obesity
Number of subjects: 10037
Study 32621730 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obese adolescents
Number of subjects: 10037
Study 32621730 — intervention group
Group type: COMPARATOR
Intervention: Private vs Government schools
Number of subjects: 10037
Study 34783626 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended Rational Emotive Behavior Therapy (REBT) for 12 weeks (2 hours weekly)
Number of subjects: 83
Study 34783626 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted group (control)
Number of subjects: 83
Study 35723940 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide 35% solution
Number of subjects: 33
Study 35723940 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 33
Study 32205449 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC
Number of subjects: 538
Study 32205449 — intervention group
Group type: COMPARATOR
Intervention: No HIPEC (Control)
Number of subjects: 538
Study 33781392 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 70
Study 33781392 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ACT)
Number of subjects: 70
Study 32114543 — intervention group
Group type: EXPERIMENTAL
Intervention: PFD or PFDD
Number of subjects: 380
Study 32114543 — intervention group
Group type: EXPERIMENTAL
Intervention: PFDD
Number of subjects: 380
Study 32114543 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative frontal‐occipital horn ratio (FOHR)
Number of subjects: 380
Study 32114543 — intervention group
Group type: EXPERIMENTAL
Intervention: Syrinx location spanning multiple spinal segments
Number of subjects: 380
Study 32114543 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoliosis
Number of subjects: 380
Study 32114543 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller syrinx diameter
Number of subjects: 380
Study 32114543 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter preoperative syrinx length
Number of subjects: 380
Study 32114543 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller pB‐C2 distance
Number of subjects: 380
Study 32114543 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age at surgery
Number of subjects: 380
Study 32114543 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased postoperative syrinx diameter
Number of subjects: 380
Study 32114543 — intervention group
Group type: COMPARATOR
Intervention: PFD versus PFDD
Number of subjects: 380
Study 34865318 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir nanofiber patch
Number of subjects: 60
Study 34865318 — intervention group
Group type: COMPARATOR
Intervention: Placebo nanofiber patch
Number of subjects: 60
Study 34865318 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir cream
Number of subjects: 60
Study 32118268 — intervention group
Group type: EXPERIMENTAL
Intervention: ENBAL
Number of subjects: 108
Study 32118268 — intervention group
Group type: COMPARATOR
Intervention: 24h fasting
Number of subjects: 108
Study 32118268 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting-induced epinephrine increase
Number of subjects: 108
Study 32756661 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oil
Number of subjects: 251
Study 32756661 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil
Number of subjects: 251
Study 32756661 — intervention group
Group type: EXPERIMENTAL
Intervention: Blend oil
Number of subjects: 251
Study 36084000 — intervention group
Group type: EXPERIMENTAL
Intervention: High-SCFA diet
Number of subjects: 20
Study 36084000 — intervention group
Group type: COMPARATOR
Intervention: Low-SCFA diet
Number of subjects: 20
Study 615706097 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream (EMLA)
Number of subjects: 22
Study 615706097 — intervention group
Group type: COMPARATOR
Intervention: Placebo (moisturising cream)
Number of subjects: 22
Study 35075816 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent physical activity intervention (40 min per day for 5/6 days per week)
Number of subjects: 160
Study 35075816 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 160
Study 35075816 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent physical activity intervention
Number of subjects: 160
Study 34389012 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible e‐learning video approach
Number of subjects: 36
Study 34389012 — intervention group
Group type: COMPARATOR
Intervention: F2F lecture-based approach
Number of subjects: 36
Study 34613454 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 392
Study 34613454 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 392
Study 34613454 — intervention group
Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 392
Study 33403727 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide inhalation (343 µg/actuation) solution
Number of subjects: 224
Study 33403727 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 µg/actuation)
Number of subjects: 224
Study 32822968 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide
Number of subjects: 3
Study 32822968 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide
Number of subjects: 3
Study 32822968 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 3
Study 32822968 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 3
Study 36222067 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated smoking cessation treatment
Number of subjects: 36
Study 36222067 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological well-being practitioners (PWPs) delivering smoking cessation intervention
Number of subjects: 36
Study 33737300 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 214
Study 33714498 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Tape™ application on GM muscle adhering to the stretching method for Kinesio Tape® application (KG, n = 17)
Number of subjects: 33
Study 33714498 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Tape™ application on GM muscle adhering to the stretching method suggested for DT (DG, n = 16)
Number of subjects: 33
Study 32384504 — intervention group
Group type: EXPERIMENTAL
Intervention: Johnson's baby shampoo top‐to‐toe (No More Tears formula)
Number of subjects: 60
Study 32384504 — intervention group
Group type: EXPERIMENTAL
Intervention: OCuSOFT Lid Scrub Original Foaming Eyelid Cleanser (OSO)
Number of subjects: 60
Study 36146946 — intervention group
Group type: EXPERIMENTAL
Intervention: Guarana (125 mg/kg)
Number of subjects: 25
Study 36146946 — intervention group
Group type: COMPARATOR
Intervention: Placebo (65 mg/kg protein powder)
Number of subjects: 25
Study 36146946 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (5 mg/kg)
Number of subjects: 25
Study 34537120 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg.kg‐1. h‐1 (Group D)
Number of subjects: 60
Study 34537120 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 15 mg.kg‐1. h‐1 (Group M)
Number of subjects: 60
Study 34537120 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Group S)
Number of subjects: 60
Study 32649925 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic monotherapy
Number of subjects: 61
Study 32649925 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention (CBT)
Number of subjects: 61
Study 32649925 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotics plus psychological intervention
Number of subjects: 61
Study 32649925 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 61
Study 35773652 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective exercises based on the Alexander posture correction technique
Number of subjects: 30
Study 35773652 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study 34521466 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycium barbarum polysaccharide (LBP) supplementation capsules
Number of subjects: 50
Study 34521466 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo capsules
Number of subjects: 50
Study 616081502 — intervention group
Group type: EXPERIMENTAL
Intervention: topical 0.1% fluorometholone
Number of subjects: 41
Study 616081502 — intervention group
Group type: COMPARATOR
Intervention: vehicle polyvinyl alcohol
Number of subjects: 41
Study 33731664 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise condition (4 kcal·kg‐1·wk‐1, 8 KKW, 12 KKW, or 20 KKW)
Number of subjects: 414
Study 32467540 — intervention group
Group type: EXPERIMENTAL
Intervention: DMTAC service (four or more visits) in addition to normal clinic visits
Number of subjects: 100
Study 32467540 — intervention group
Group type: COMPARATOR
Intervention: Normal clinic visits with consultations by a medical officer
Number of subjects: 100
Study 32467540 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (control and intervention)
Number of subjects: 100
Study 34855996 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision of ulcerated skin cancer
Number of subjects: 148
Study 34855996 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision of ulcerated skin cancer with wounds healing by secondary intention
Number of subjects: 148
Study 32621467 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam (16 mg/day for 2 days)
Number of subjects: 108
Study 32621467 — intervention group
Group type: COMPARATOR
Intervention: Xefocam (lyophilisate for preparation of solution for intravenous and intramuscular injection)
Number of subjects: 108
Study 33616618 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Number of subjects: 0
Study 32497219 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 312
Study 32497219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 35283261 — intervention group
Group type: EXPERIMENTAL
Intervention: EX+DWL (exercise combined with dietary weight loss)
Number of subjects: 0
Study 35283261 — intervention group
Group type: COMPARATOR
Intervention: WWE (Walk With Ease) standard of care self-management program
Number of subjects: 0
Study 32553589 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical management (NSM) including radiation therapy (71% of NSM), hormonal therapy (25% of NSM), and both (4% of NSM)
Number of subjects: 112469
Study 32553589 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 112469
Study 32553589 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical management (NSM)
Number of subjects: 112469
Study 35867804 — intervention group
Group type: EXPERIMENTAL
Intervention: istaroxime 1.0 - 1.5 μg/kg/min
Number of subjects: 60
Study 34369043 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pandemic social support
Number of subjects: 100
Study 34369043 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pandemic depressive symptoms
Number of subjects: 100
Study 34369043 — intervention group
Group type: EXPERIMENTAL
Intervention: Life disruptions due to the pandemic
Number of subjects: 100
Study 34369043 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of color
Number of subjects: 100
Study 35264615 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet ventilation (HV) during 6 minute walk test (6MWT)
Number of subjects: 20
Study 34292427 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign molecular test result
Number of subjects: 252
Study 34292427 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspicious molecular test result
Number of subjects: 252
Study 34292427 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 252
Study 32539783 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide for 12 weeks
Number of subjects: 38
Study 35656943 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech COVID-19 vaccine
Number of subjects: 187
Study 35656943 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-vaccinated COVID-19 negative patients)
Number of subjects: 187
Study 33280101 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporalis muscle measurements
Number of subjects: 50
Study 33280101 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of temporal crest
Number of subjects: 50
Study 33216623 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition supplementation (whey protein, fish oil, vitamin D)
Number of subjects: 241
Study 33216623 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (resistance and aerobic exercise)
Number of subjects: 241
Study 33216623 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition combined with exercise
Number of subjects: 241
Study 33216623 — intervention group
Group type: COMPARATOR
Intervention: Routine consultation
Number of subjects: 241
Study 33137581 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Focus (internal plus external)
Number of subjects: 90
Study 33137581 — intervention group
Group type: EXPERIMENTAL
Intervention: External Focus
Number of subjects: 90
Study 35317850 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injection to the vocal cord contralateral to the lesion
Number of subjects: 20
Study 35317850 — intervention group
Group type: COMPARATOR
Intervention: No injection (control group)
Number of subjects: 20
Study 34971304 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of bupivacaine (3 mL of 0.5% plain bupivacaine hydrochloride)
Number of subjects: 40
Study 34971304 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (3 mL)
Number of subjects: 40
Study 33910138 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions designed to enhance self-regulation (executive functioning, emotion regulation, future-oriented thinking, approach biases)
Number of subjects: 118
Study 33910138 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions
Number of subjects: 118
Study 34934307 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 0.5 mg/kg for 5 min before anesthesia induction, maintained at 0.5 mg/kg/h
Number of subjects: 125
Study 34934307 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 1.0 mg/kg for 5 min before anesthesia induction, maintained at 2.0 mg/kg/h
Number of subjects: 125
Study 34934307 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.75 mL/kg/h for 5 min before anesthesia induction, maintained at 0.25 mL/kg/h
Number of subjects: 125
Study 34569486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg/day)
Number of subjects: 131
Study 34569486 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (500 mg/m2 + 2 for 6 cycles)
Number of subjects: 131
Study 34569486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 131
Study 34569486 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 131
Study 33984668 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured physical activity intervention (60 min per meeting, 5 times per week, over 12 months)
Number of subjects: 42
Study 33984668 — intervention group
Group type: COMPARATOR
Intervention: Supervised free play program (60 min per meeting, 5 times per week, over 12 months)
Number of subjects: 42
Study 36130761 — intervention group
Group type: EXPERIMENTAL
Intervention: Early near vision correction with spectacles (+3.00 DS) prescribed for full-time wear, with intervention at 8 weeks corrected gestational age (Group B1) or 16 weeks corrected gestational age (Group B2).
Number of subjects: 75
Study 36130761 — intervention group
Group type: COMPARATOR
Intervention: Standard care - waiting until a problem is detected (Group A).
Number of subjects: 75
Study 32126750 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of propofol (CI group)
Number of subjects: 232
Study 32126750 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus injection of propofol (BI group)
Number of subjects: 232
Study 34817126 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) - 660 nm, 100 mW, 177 J/cm2, 5 s, 0.5 J per point
Number of subjects: 34
Study 34817126 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05% (Control)
Number of subjects: 34
Study 34817126 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PBM and Control)
Number of subjects: 34
Study 33199490 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Bevacizumab (cohort A, n = 50)
Number of subjects: 80
Study 33199490 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab alone (cohort B, n = 30)
Number of subjects: 80
Study 32053162 — intervention group
Group type: EXPERIMENTAL
Intervention: Heading group (10 headers with soccer balls at 25 mph)
Number of subjects: 67
Study 32053162 — intervention group
Group type: COMPARATOR
Intervention: Kicking-control group (10 kicks)
Number of subjects: 67
Study 32053162 — intervention group
Group type: COMPARATOR
Intervention: Comparison of groups
Number of subjects: 67
Study 35534494 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 1 mg/kg/day (max 60 mg/day) alone
Number of subjects: 44
Study 35534494 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 1 mg/kg/day (max 60 mg/day) with methotrexate 0.3 mg/kg/week for 9 months
Number of subjects: 44
Study 33908665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine mini-lozenge
Number of subjects: 577
Study 33908665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine mini-lozenge + Reduction counseling
Number of subjects: 577
Study 33908665 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction counseling
Number of subjects: 577
Study 34757134 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic formula (Lactobacillus acidophilus LA‐5, Lactobacillus plantarum, Bifidobacterium lactis BB‐12, Saccharomyces boulardii) administered as two sachets twice daily for 15 days
Number of subjects: 112
Study 34757134 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic formula
Number of subjects: 112
Study 34757134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 32009500 — intervention group
Group type: EXPERIMENTAL
Intervention: PedsQL Family Impact Module
Number of subjects: 58
Study 32009500 — intervention group
Group type: EXPERIMENTAL
Intervention: Child self-report and proxy report surveys
Number of subjects: 58
Study 32009500 — intervention group
Group type: COMPARATOR
Intervention: Gastrostomy tube
Number of subjects: 58
Study 32009500 — intervention group
Group type: COMPARATOR
Intervention: Ventilation support
Number of subjects: 58
Study 32009500 — intervention group
Group type: COMPARATOR
Intervention: Nusinersen use
Number of subjects: 58
Study 32009500 — intervention group
Group type: COMPARATOR
Intervention: Spinal surgery
Number of subjects: 58
Study 91005492 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune gamma-globulin given to the neonates born of mothers with hepatitis A
Number of subjects: 34
Study 91005492 — intervention group
Group type: COMPARATOR
Intervention: Pregnant women with hepatitis A
Number of subjects: 34
Study 35717262 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum message and chart
Number of subjects: 1851
Study 35717262 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall-prescribing message with a chart
Number of subjects: 1851
Study 33050928 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg administered subcutaneously every 4 weeks
Number of subjects: 0
Study 33050928 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0
Study 33050928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35191525 — intervention group
Group type: EXPERIMENTAL
Intervention: iACT group
Number of subjects: 182
Study 35191525 — intervention group
Group type: COMPARATOR
Intervention: WLC group
Number of subjects: 182
Study 33743799 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (1 unit, 200-399 mL)
Number of subjects: 1000
Study 33743799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 33743799 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma
Number of subjects: 1000
Study 32726793 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training as part of a 19-week rehabilitation program (3 weeks inpatient, 16 weeks at home).
Number of subjects: 45
Study 32726793 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training as part of a 19-week rehabilitation program.
Number of subjects: 45
Study 35900726 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib, 1 mg orally daily and avelumab, 10 mg/kg intravenously every 2 weeks
Number of subjects: 35
Study 35900726 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib and avelumab
Number of subjects: 35
Study 34116652 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-gene prognostic signature (TPM1, SLC2A1, CDCA8, ATG10, HOXD9)
Number of subjects: 374
Study 34116652 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on the 5-gene signature
Number of subjects: 374
Study 34116652 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram incorporating the 5-gene signature and clinical features
Number of subjects: 374
Study 34116652 — intervention group
Group type: EXPERIMENTAL
Intervention: GSEA analysis of low- and high-risk groups
Number of subjects: 374
Study 32871992 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive psychosomatic promotion
Number of subjects: 80
Study 33557654 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 15
Study 32144172 — intervention group
Group type: EXPERIMENTAL
Intervention: iStep‐MS intervention (four therapist‐led sessions over 12 weeks, supported by a handbook and pedometer)
Number of subjects: 60
Study 32144172 — intervention group
Group type: EXPERIMENTAL
Intervention: iStep‐MS intervention
Number of subjects: 60
Study 32144172 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 60